Archive: Company News
Company News: Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections; Presents at Key Investor and Scientific Conferences in Q1, 2017
– Highly multiplexed panel covers up to 112 diagnostic targets
– Third new panel developed within one year after IPO
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the completion of development of its fourth Application Cartridge.
Company News: BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017
BioNTech AG, a fully integrated biotechnology company developing truly individualized cancer immunotherapies, today announced that Sean Marett, COO of BioNTech, will be presenting at 35th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA January 9 – 12, 2017. The presentation is scheduled for Wednesday, January 11th at 9:30 AM Pacific Standard Time. Mr. Marett will provide an overview of the company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer vaccines and the establishment of a second mRNA production facility at the Company´s headquarters in Germany.
The J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends.
Company News: Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec
– Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-answer molecular diagnostic testing
– Gyronimo to be fully integrated into Unyvero Platform and suite of products
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the acquisition of the real-time qPCR-based Gyronimo Platform from Carpegen GmbH and Systec GmbH, joint owners of the platform.
Company News: #investEU – Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform
– European Investment Bank (EIB) provides EUR 10 million immediately, with a further EUR 15 million available upon meeting certain milestones
– Transaction is guaranteed by the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe
– Financing allows strategic expansion and further development of Unyvero Platform
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, and the European Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25 million senior, unsecured loan. The financing is the first growth capital loan under the European Growth Finance Facility (EGFF), launched in November 2016.